These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 1902238)
1. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. Fleishaker JC; Phillips JP J Clin Pharmacol; 1991 Mar; 31(3):259-62. PubMed ID: 1902238 [TBL] [Abstract][Full Text] [Related]
2. The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects. Boni JP; Cevallos WH; DeCleene S; Korth-Bradley JM Pharmacotherapy; 1997; 17(4):783-90. PubMed ID: 9250558 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Brier ME; Bays H; Sloan R; Stalker DJ; Welshman I; Aronoff GR Am J Kidney Dis; 1997 Jun; 29(6):907-11. PubMed ID: 9186077 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus. Jaber LA; Antal EJ; Welshman IR Ann Pharmacother; 1996 May; 30(5):472-5. PubMed ID: 8740326 [TBL] [Abstract][Full Text] [Related]
5. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Kubacka RT; Antal EJ; Juhl RP; Welshman IR Ann Pharmacother; 1996 Jan; 30(1):20-6. PubMed ID: 8773160 [TBL] [Abstract][Full Text] [Related]
6. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Min B; Guerciolini R; Freundlich NL; Milla G; Patel IH J Clin Pharmacol; 1995 May; 35(5):521-5. PubMed ID: 7657854 [TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. Jaber LA; Antal EJ; Slaughter RL; Welshman IR Diabetes Care; 1994 Nov; 17(11):1300-6. PubMed ID: 7821171 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Schwinghammer TL; Antal EJ; Kubacka RT; Hackimer ME; Johnston JM Clin Pharm; 1991 Jul; 10(7):532-8. PubMed ID: 1907234 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Jaber LA; Antal EJ; Slaughter RL; Welshman IR Eur J Clin Pharmacol; 1993; 45(5):459-63. PubMed ID: 8112376 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589 [TBL] [Abstract][Full Text] [Related]
11. Low-dose oral glyburide reduces fasting blood glucose by decreasing hepatic glucose production in healthy volunteers without increasing carbohydrate oxidation. Tayek JA Am J Med Sci; 1995 Mar; 309(3):134-9. PubMed ID: 7879817 [TBL] [Abstract][Full Text] [Related]
12. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Damsbo P; Clauson P; Marbury TC; Windfeld K Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683 [TBL] [Abstract][Full Text] [Related]
13. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT Clin Pharmacol Ther; 2001 Jun; 69(6):400-6. PubMed ID: 11406737 [TBL] [Abstract][Full Text] [Related]
14. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Rao N; Chou T; Ventura D; Abramowitz W Clin Ther; 2005 Oct; 27(10):1596-606. PubMed ID: 16330295 [TBL] [Abstract][Full Text] [Related]
15. An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus. Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL Clin Drug Investig; 2013 Dec; 33(12):929-38. PubMed ID: 24132772 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide. Jaber LA; Wenzloff NJ; Komanicky P; Antal EJ J Clin Pharmacol; 1990 Feb; 30(2):181-8. PubMed ID: 2107214 [TBL] [Abstract][Full Text] [Related]
17. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533 [TBL] [Abstract][Full Text] [Related]
18. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664 [TBL] [Abstract][Full Text] [Related]
19. Effects of oral erythromycin on upper gastrointestinal motility in patients with non-insulin-dependent diabetes mellitus. Kao CH; Wang SJ; Pang DY Nucl Med Commun; 1995 Sep; 16(9):790-3. PubMed ID: 7478413 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of glyburide in patients with well-controlled diabetes. Tracewell WG; Stalker DJ; Maloley PA; Gallagher TF; Gwilt PR Pharmacotherapy; 1998; 18(1):51-6. PubMed ID: 9469681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]